Gene therapy using Aβ variants for amyloid reduction

Kyung Won Park, Caleb A. Wood, Jun Li, Bethany C. Taylor, Sae Woong Oh, Nicolas L. Young, Joanna L. Jankowsky

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

Numerous aggregation inhibitors have been developed with the goal of blocking or reversing toxic amyloid formation in vivo. Previous studies have used short peptide inhibitors targeting different amyloid β (Aβ) amyloidogenic regions to prevent aggregation. Despite the specificity that can be achieved by peptide inhibitors, translation of these strategies has been thwarted by two key obstacles: rapid proteolytic degradation in the bloodstream and poor transfer across the blood-brain barrier. To circumvent these problems, we have created a minigene to express full-length Aβ variants in the mouse brain. We identify two variants, F20P and F19D/L34P, that display four key properties required for therapeutic use: neither peptide aggregates on its own, both inhibit aggregation of wild-type Aβ in vitro, promote disassembly of pre-formed fibrils, and diminish toxicity of Aβ oligomers. We used intraventricular injection of adeno-associated virus (AAV) to express each variant in APP/PS1 transgenic mice. Lifelong expression of F20P, but not F19D/L34P, diminished Aβ levels, plaque burden, and plaque-associated neuroinflammation. Our findings suggest that AAV delivery of Aβ variants may offer a novel therapeutic strategy for Alzheimer's disease. More broadly our work offers a framework for identifying and delivering peptide inhibitors tailored to other protein-misfolding diseases.

Original languageEnglish (US)
Pages (from-to)2294-2307
Number of pages14
JournalMolecular Therapy
Volume29
Issue number7
DOIs
StatePublished - Jul 7 2021

Keywords

  • APP/PS1 mouse
  • P0 injection
  • amyloid
  • peptide inhibitor
  • viral vector

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery

Fingerprint

Dive into the research topics of 'Gene therapy using Aβ variants for amyloid reduction'. Together they form a unique fingerprint.

Cite this